Influence of gut microbiome on multiple myeloma: friend or foe? by Marcos de Lima, Nausheen Ahmed, Mahmoud Ghannoum, Molly Gallogly, Ehsan Malek

Get full text

The current socioeconomic and regulatory landscape of immune effector cell therapies by Chiranjeevi Sainatham, Devvrat Yadav, Aravind Dilli Babu, Jayanth Reddy Tallapalli, Sai Gautham Kanagala, Evgenii Filippov, Franco Murillo Chavez, Nausheen Ahmed, Forat Lutfi

Get full text

Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis by Amneet Bajwa, Qiuhong Zhao, Marcus Geer, Chenyu Lin, James Westholder, Joseph Maakaron, Monalisa Ghosh, David Frame, Ahmed Galal, Justin Tossey, Nausheen Ahmed, Evandro Bezerra, Nathan Denlinger, Marcos de Lima, Narendranath Epperla, Paolo Caimi, Timothy Voorhees

Get full text

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy by Maximilian Merz, Danai Dima, Hamza Hashmi, Nausheen Ahmed, Friedrich Stölzel, Tobias A. W. Holderried, Roland Fenk, Fabian Müller, Natalia Tovar, Aina Oliver-Cáldes, Kristin Rathje, James A. Davis, David Fandrei, Vladan Vucinic, Soraya Kharboutli, Ben-Niklas Baermann, Francis Ayuk, Uwe Platzbecker, Anca-Maria Albici, Nathalie Schub, Friederike Schmitz, Leyla Shune, Jack Khouri, Faiz Anwer, Shahzad Raza, Joseph McGuirk, Zahra Mahmoudjafari, Kimberly Green, Cyrus Khandanpour, Marcel Teichert, Barbara Jeker, Michele Hoffmann, Nicolaus Kröger, Bastian von Tresckow, Carlos Fernández de Larrea, Thomas Pabst, Al-Ola Abdallah, Nico Gagelmann

Get full text